The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.